Viatris Inc operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Viatris Inc with three other companies in this sector in UNITED STATES : Regeneron Pharmaceuticals Incorporated (2019 sales of $7.86 billion of which 59% was EYLEA), Daiichi Sankyo Company Limited ($8.38 billion of which 93% was Prescription drugs), and CSL Limited ($8.54 billion of which 84% was CSL Behring).

Sales Analysis. During the year ended December of 2019, sales at Viatris Inc were $11.50 billion. This is a very small increase of 0.6% versus 2018, when the company's sales were $11.43 billion. Despite this increase, sales are still below the level achieved in 2017, when Viatris Inc reported sales of $11.91 billion. Sales of Rest of World saw an increase that was more than double the company's growth rate: sales were up 5.5% in 2019, from $3.04 billion to $3.21 billion. Not all segments of Viatris Inc experienced an increase in sales in 2019: sales of Europe fell 3.1% to $4.05 billion.